What Is CAR-T Cell Therapy? A Patient Guide to This Advanced Cancer Treatment in China
CAR-T cell therapy is an advanced form of immunotherapy that uses genetically modified immune cells to target cancer. This guide explains how CAR-T therapy works, who may benefit, the treatment process, and why China has become an important destination for CAR-T treatment and research.
TAZVERIK (tazemetostat)
Tazemetostat is a first-in-class EZH2 inhibitor approved for advanced epithelioid sarcoma and certain R/R FL patients. Now available in China, it restores tumor suppressor gene expression to control tumor growth.
NMPA Approval for Relmacabtagene Autoleucel (Carteyva) for Relapsed Large B-Cell Lymphoma
China approves relmacabtagene autoleucel (Carteyva®), a breakthrough CAR-T therapy for relapsed or refractory large B-cell lymphoma, offering new hope for durable remission.
China Approves First Cell Therapy Product, Opening a New Chapter in Cancer Treatment
Recently, China approved its first commercial cell therapy product—marking a major milestone in the country’s biopharmaceutical landscape.